FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December 2016
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
05
December 2016 07:00
ASTRAZENECA COMPLETES AGREEMENT WITH
CILAG GMBH INTERNATIONAL FOR RIGHTS
TO RHINOCORT AQUA OUTSIDE THE US
AstraZeneca today announced that it has completed the
agreement
with Cilag GmbH International, an
affiliate of Johnson & Johnson, for the divestment of
the rights to Rhinocort
Aqua outside the
US. Rhinocort
Aqua is a nasal spray indicated for allergic and
non-allergic rhinitis (inflammation of the inside of the
nose), and for the treatment of nasal polyps (swelling of the
nasal lining).
Under
the terms of the agreement, AstraZeneca has received a payment of
$330 million from Cilag GmbH International for the rights to the
medicine outside the US. As AstraZeneca will not maintain a
significant ongoing interest in Rhinocort Aqua, the payment will be
recognised as Other Operating Income in the Company's financial
statements, and will be booked in the fourth quarter of
2016.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media Enquiries
|
|
|
|
Neil Burrows
|
UK/Global
|
+44 203 749 5637
|
|
Vanessa Rhodes
|
UK/Global
|
+44 203 749 5736
|
|
Karen Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Jacob Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele Meixell
|
US
|
+1 302 885 2677
|
|
|
|
|
|
Investor Relations
|
|
|
|
Thomas Kudsk Larsen
|
|
+44 203 749 5712
|
|
Craig Marks
|
Finance, Fixed Income, M&A
|
+44 7881 615 764
|
|
Henry Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Mitchell Chan
|
Oncology
|
+1 240 477 3771
|
|
Lindsey Trickett
|
Cardiovascular & Metabolic Diseases
|
+1 240 543 7970
|
|
Nick Stone
|
Respiratory
|
+44 203 749 5716
|
|
Christer Gruvris
|
Autoimmunity, neuroscience & infection
|
+44 203 749 5711
|
|
US toll free
|
|
+1 866 381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
|
Date:
05 December 2016
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|